A Phase 3 interventional study of IV Dalbavancin and Vancomycin/Linezolid in Abscess, Wound Infection and Surgical Site Infection, sponsored by Durata Therapeutics Inc., an affiliate of Allergan plc. Completed at 137 sites in 14 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-02-12.
Sponsored by Durata Therapeutics Inc., an affiliate of Allergan plc (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Abscess with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Abscess · United States.
Among the 80 studies in Abscess with a site in United States, this one is the 8th largest by enrollment of the 75 interventional ones that give a count, is one of 6 that started in 2011, is one of 13 in phase 3, and was the 40th registered.
152 studies on the registry are indexed under Abscess; 22 are open to participants now.
Browse Abscess studies →4 of the 80 studies in Abscess with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Loyola University · Sites in United States
Ages 7–70
University of Rochester · Sites in United States
Ages 18+
University of Rochester · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Abscess studies recruiting now, 5 (45%) set no upper age limit and 5 (45%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 17 · Phase 3 13 · Phase 4 9
First in 2003; this study’s year is marked. 6 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 739 is above the median of 110 across 120 interventional studies indexed under Abscess.
Median enrollment 114 across the 75 interventional studies, 420 across the 5 observational. Of the 72 that completed or were terminated, 45 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 80 have an industry lead sponsor. The 10 most frequent:
This study is registered under Durata Therapeutics Inc., an affiliate of Allergan plc, one of the names counted as AbbVie. Under that name alone:
Durata Therapeutics Inc., an affiliate of Allergan plc is the lead sponsor of 6 studies on the registry; none are open to participants now.
AbbVie has 8 studies filed under Abscess — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 80 studies in Abscess with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a suspected or proved gram-positive bacterial skin or skin structure infections.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients presenting with any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Vancomycin/Linezolid
Drug: IV Dalbavancin
IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8
Drug pages: VancomycinStudies of VancomycinVancomycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LinezolidStudies of LinezolidLinezolid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg every 12 hours). Total duration of therapy is 10-14 days
Early Clinical Efficacy
Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size and temperature
Time frame: After 48-72 hours of therapy
Clinical Status
Compare the clinical efficacy at end of treatment visit of dalbavancin to the comparator regimen based on lesion size, local signs, temperature and receipt of other therapy
Time frame: End of Treatment Visit (Day 14-15)
>= 20% Reduction in Lesion Area
Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size
Time frame: 48-72 hours after the initiation of study therapy
Clinical Status
Compare the clinical efficacy at the short term follow-up visit of dalbavancin to the comparator regimen based on lesion size, local signs temperature and receipt of other therapy
Time frame: Follow-Up Visit (day 28)
| Milestone | Dalbavancin | Vancomycin With Possible Switch to Oral Linezolid |
|---|---|---|
| Started | 371 | 368 |
| Safety population | 368 | 367 |
| Completed | 332 | 333 |
| Not completed | 39 | 35 |
Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size and temperature
| participants | Dalbavancin | Vancomycin With Possible Switch to Oral Linezolid |
|---|---|---|
| Clinical Responder | 285 | 288 |
| Clinical Non-Responder | 86 | 80 |
Compare the clinical efficacy at end of treatment visit of dalbavancin to the comparator regimen based on lesion size, local signs, temperature and receipt of other therapy
| participants | Dalbavancin | Vancomycin With Possible Switch to Oral Linezolid |
|---|---|---|
| Clinical Succcess | 303 | 280 |
| Clinical Failure | 21 | 22 |
Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size
| participants | Dalbavancin | Vancomycin With Possible Switch to Oral Linezolid |
|---|---|---|
| Clinical Responder | 325 | 316 |
| Clinical Non-Responder | 46 | 52 |
Compare the clinical efficacy at the short term follow-up visit of dalbavancin to the comparator regimen based on lesion size, local signs temperature and receipt of other therapy
| participants | Dalbavancin | Vancomycin With Possible Switch to Oral Linezolid |
|---|---|---|
| Clinical Success | 283 | 257 |
| Clinical Failure | 11 | 15 |
Collected over Begins from the time that the patient provides informed consent through the last follow up visit, Day 70. Any SAE occurring any time after the reporting period must be promptly reported if a causal relationship to investigational product is suspected.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dalbavancin | — | 12/368 (3.3%) | 29/368 (7.9%) |
| Vancomycin With Possible Switch to Oral Linezolid | — | 14/367 (3.8%) | 28/367 (7.6%) |
| Event | Dalbavancin | Vancomycin With Possible Switch to Oral Linezolid |
|---|---|---|
| CellulitisInfections and infestations | 3/368 | 0/367 |
| GangreneInfections and infestations | 0/368 | 2/367 |
| Systemic inflammatory response syndromeGeneral disorders | 0/368 | 1/367 |
| ErythemaSkin and subcutaneous tissue disorders | 0/368 | 1/367 |
| Blood glucose increasedInvestigations | 0/368 | 1/367 |
| AbscessInfections and infestations | 0/368 | 1/367 |
| Cholecystitis acuteHepatobiliary disorders | 0/368 | 1/367 |
| Gastrointestinal disorderGastrointestinal disorders | 0/368 | 1/367 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 0/368 | 1/367 |
| Renal failure acuteRenal and urinary disorders | 0/368 | 1/367 |
| Event | Dalbavancin | Vancomycin With Possible Switch to Oral Linezolid |
|---|---|---|
| NauseaGastrointestinal disorders | 15/368 | 15/367 |
| HeadacheNervous system disorders | 11/368 | 9/367 |
| DiarrhoeaGastrointestinal disorders | 4/368 | 8/367 |
| VomitingGastrointestinal disorders | 8/368 | 4/367 |
| Age, Continuous(years) | Dalbavancin | Vancomycin With Possible Switch to Oral Linezolid | Total |
|---|---|---|---|
| Mean | 49.1 ± 16.54 | 51.4 ± 16.16 | 50.2 ± 16.38 |
| Sex: Female, Male(Participants) | Dalbavancin | Vancomycin With Possible Switch to Oral Linezolid | Total |
|---|---|---|---|
| Female | 148 | 167 | 315 |
| Male | 223 | 201 | 424 |
Showing the first 100 of 137 sites across 14 countries. Choose a country and city above to see the rest.
The record gives a start of Jul 2011, a primary completion of Nov 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2014, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dalbavancin
Durata Therapeutics Inc., an affiliate of Allergan plc →